On August 3, AstraZeneca PLC fell 7.22% in regular trading, trading at $157.38/share, with turnover of $200 million.

On the news front, AstraZeneca PLC is reportedly in talks with Bristol-Myers Squibb about a potential combination that would create a pharmaceutical company valued at nearly $400 billion, ranking among the largest pharmaceutical mergers ever. The discussions have been ongoing for several months, though a deal could still be delayed or fail to materialize. The transaction would likely be structured as a mix of cash and stock.

AstraZeneca PLC currently has a market capitalization of approximately $264 billion, while Bristol-Myers Squibb is valued at around $133 billion. Bristol-Myers Squibb is preparing for patent expirations on core products Eliquis and Opdivo, which together account for roughly half of its sales. The market is concerned about acquisition premiums and integration risks given heavy overlap in oncology portfolios, with cancer drugs contributing approximately 44% and 50% of each company's revenue respectively. Bristol-Myers Squibb shares rose over 4% in contrast.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)